Wisdom Bioscience, founded in 2024 with a laboratory in Daresbury, is building a platform that detects oral cancer through a simple, non-invasive test based on circulating cell-free DNA. By integrating advanced genomic technologies directly into dental workflows, the company aims to make early oral cancer screening a routine part of dental visits. Recent company milestones include assembling a Scientific Advisory Board comprised of leading figures in oncology screening and molecular diagnostics to guide product development and commercialization strategy. Proceeds from its latest funding are earmarked for continued clinical validation studies and preparing a commercial launch later in 2024. Investors such as Stephen Quake and Jay Flatley back the company, underscoring strong industry confidence. Collectively, Wisdom has secured $28 million in funding since inception, positioning it to accelerate regulatory, clinical, and go-to-market efforts.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2026